Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands

<p>Abstract</p> <p>Background</p> <p>This study compares the costs and effects of a regimen with ritonavir-boosted tipranavir (TPV/r) to a physician-selected genotypically-defined standard-of-care comparator protease inhibitor regimen boosted with ritonavir (CPI/r) in HIV infected patients that were...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kappelhoff Bregt S, Finnern Henrik W, Stegmeijer Simon, Veltman-Starkenburg Christa A, Bos Jasper M, Hubben Gijs AA, Simpson Kit N, Tramarin Andrea, Postma Maarten J
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2007-11-01
Edice:	Cost Effectiveness and Resource Allocation
On-line přístup:	http://www.resource-allocation.com/content/5/1/15
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!